Cost savings associated with the adoption of lower-dose everolimus in patients with advanced neuroendocrine tumors

Background: Everolimus is effective in advanced neuroendocrine tumors (NETs) but is associated with substantial toxicity and high long-term costs. Real-world data suggest that lower doses (≤6 mg/day) achieve comparable efficacy with reduced toxicity compared with standard-dose therapy. This study ai...

Descrición completa

Detalles Bibliográficos

Principais autores:	G.R. de Almeida, R.P. Riechelmann, A.B. Brito, R.G. Taboada, A.L.M. da Silva, R.F. Weschenfelder, A.P.B.S. Etges
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2026-06-01
Series:	ESMO Gastrointestinal Oncology
Assuntos:	cost minimization everolimus neuroendocrine tumors economic analysis microcosting
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2949819826000373
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!